443 related articles for article (PubMed ID: 8043488)
1. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
2. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
Feelders RA; Hofland LJ; de Herder WW
Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
[TBL] [Abstract][Full Text] [Related]
3. [Medical treatment for Cushing's syndrome].
Nishikawa T; Saito J; Omura M
Nihon Rinsho; 2008 Jan; 66(1):186-91. PubMed ID: 18186263
[TBL] [Abstract][Full Text] [Related]
4. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome.
Engelhardt D; Jacob K; Doerr HG
Klin Wochenschr; 1989 Feb; 67(4):241-7. PubMed ID: 2538676
[TBL] [Abstract][Full Text] [Related]
5. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of pharmacological treatment of Cushing's syndrome].
Saito J; Nishikawa T
Nihon Rinsho; 1994 Mar; 52(3):793-6. PubMed ID: 8164384
[TBL] [Abstract][Full Text] [Related]
7. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological therapy of Cushing's syndrome: drugs and indications.
Díez JJ; Iglesias P
Mini Rev Med Chem; 2007 May; 7(5):467-80. PubMed ID: 17504182
[TBL] [Abstract][Full Text] [Related]
9. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
10. Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice.
Igaz P; Tömböl Z; Szabó PM; Likó I; Rácz K
Curr Med Chem; 2008; 15(26):2734-47. PubMed ID: 18991633
[TBL] [Abstract][Full Text] [Related]
11. Aminoglutethimide and metyrapone in the management of Cushing's syndrome.
Thorén M; Adamson U; Sjöberg HE
Acta Endocrinol (Copenh); 1985 Aug; 109(4):451-7. PubMed ID: 3898689
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells.
Lamberts SW; Bons EG; Bruining HA; de Jong FH
J Pharmacol Exp Ther; 1987 Jan; 240(1):259-64. PubMed ID: 3027305
[TBL] [Abstract][Full Text] [Related]
13. Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole.
Berwaerts JJ; Verhelst JA; Verhaert GC; Verhaegen AA; Abs RE
J Am Geriatr Soc; 1998 Jul; 46(7):880-4. PubMed ID: 9670876
[TBL] [Abstract][Full Text] [Related]
14. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
15. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
Verhelst JA; Trainer PJ; Howlett TA; Perry L; Rees LH; Grossman AB; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1991 Aug; 35(2):169-78. PubMed ID: 1657460
[TBL] [Abstract][Full Text] [Related]
16. New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line.
Fassnacht M; Hahner S; Beuschlein F; Klink A; Reincke M; Allolio B
Eur J Clin Invest; 2000 Dec; 30 Suppl 3():76-82. PubMed ID: 11281374
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
Komanicky P; Spark RF; Melby JC
J Clin Endocrinol Metab; 1978 Nov; 47(5):1042-51. PubMed ID: 233687
[TBL] [Abstract][Full Text] [Related]
19. Use of ketoconazole in the treatment of Cushing's syndrome.
Loli P; Berselli ME; Tagliaferri M
J Clin Endocrinol Metab; 1986 Dec; 63(6):1365-71. PubMed ID: 3023421
[TBL] [Abstract][Full Text] [Related]
20. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients.
Sonino N; Boscaro M; Paoletta A; Mantero F; Ziliotto D
Clin Endocrinol (Oxf); 1991 Oct; 35(4):347-52. PubMed ID: 1752063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
